[1]袁 源),刘宏伟)#,刘春华),等.河南省商丘市艾滋病抗病毒治疗病毒未抑制患者HIV-1耐药毒株的变异*[J].郑州大学学报(医学版),2016,(05):643-646.
 YUAN Yuan),LIU Hongwei),LIU Chunhua),et al.Genotype resistant mutations among patients failed to high antiretroviral therapy in Henan Province[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(05):643-646.
点击复制

河南省商丘市艾滋病抗病毒治疗病毒未抑制患者HIV-1耐药毒株的变异*()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2016年05期
页码:
643-646
栏目:
应用研究
出版日期:
2016-08-20

文章信息/Info

Title:
Genotype resistant mutations among patients failed to high antiretroviral therapy in Henan Province
作者:
袁 源1)刘宏伟1)#刘春华1)王 哲1)阮玉华2)邢 辉2)
1)河南省疾病预防控制中心性病艾滋病研究所 郑州 450016;2)中国疾病预防控制中心性病艾滋病预防控制中心 北京 100050
Author(s):
YUAN Yuan1)LIU Hongwei1)LIU Chunhua1)WANG Zhe1)RUAN Yuhua2)XING Hui2)
1)Institute for AIDS/STD Control and Prevention, Henan Center for Disease Control and Prevention,Zhengzhou 450016;2)National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206
关键词:
人类免疫缺陷病毒 耐药 抗病毒治疗 基因突变 河南省
Keywords:
human immunodeficiency virus drug resistance antiretroviral treatment gene mutation Henan Province
分类号:
R183.9
摘要:
目的:了解河南省商丘市艾滋病一线抗病毒治疗病毒未抑制患者HIV-1耐药毒株的变异。方法:采集河南省商丘市一线抗病毒治疗大于6个月、病毒未抑制的艾滋病患者血样231份,提取RNA,通过逆转录及巢式PCR扩增HIV-1 pol区基因,所得扩增片段进行测序后提交斯坦福大学HIV耐药数据库进行基因型耐药性分析。结果:在231份样本中,229份扩增并测序成功,共获得229例患者蛋白酶区和逆转录酶区的基因扩增片段。针对非核苷类逆转录酶抑制剂(NNRTIs)、核苷类逆转录酶抑制剂(NRTIs)和蛋白酶抑制剂(PIs),分别有185例(80.79%)、150例(65.50%)和3例(1.31%)发生耐药性突变,针对上述各抑制剂发生最多的耐药性突变分别为K103N/S 45.42%(104/229)、M184I/V 43.67%(100/229)和M46I 0.87%(2/229),其中与病毒载量5~ lg拷贝/mL相比,M184I/V耐药性突变在患者体内病毒载量3~拷贝/mL时更易出现(OR=0.283,95%CI为0.136~0.592,P<0.001),与治疗时间6~个月相比,K103N/S耐药性突变在患者治疗时间48~个月时更易出现(OR=7.422,95%CI为1.637~33.651,P<0.001),K65R突变位点在使用含D4T一线抗病毒治疗方案患者中发生率较高(P=0.044)。结论:河南省商丘市抗病毒治疗病毒未抑制人群中耐药性突变位点多、类型复杂,应根据耐药突变情况选用更适合的抗病毒起始治疗方案,以减少耐药毒株的产生。
Abstract:
Aim: To analyze the prevalence and diversity of genotype resistant mutations among patients failed to high antiretroviral therapy(HAART)in Henan Province.Methods: A total of 231 serum specimens of AIDS individuals with virus load ≥1 000 copies/mL were collected and had received more than six months treatment with HAART.The HIV-1 pol gene was amplified by RT-PCR,the sequences were then submitted to the Stanford University HIV drug resistance database to analyze the prevalence of resistant mutations.Results: A total of 229 plasma samples were amplified successfully for protease and reverse transcriptase fragments.Out of 229 sequences,185(80.79%),150(65.50%)and 3(1.31%)sequences occurred resistance mutations for non-nucleotide reverse transcriptase inhibitors(NNRTIs),nucleotide reverse transcriptase inhibitors(NRTIs)and protease inhibitors(PIs), respectively.The most common mutations to NNRTIs, NRTIs, and PIs were K103N/S 45.42%(104/229), M184I/V 43.67%(100/229)and M46I 0.87%(2/229), respectively. Univariate logistic regression analysis showed that among AIDS individuals, virus load 5- lg copies/mL decreased the risk of M184I/V mutation(OR=0.283,95%CI=0.136-0.592,P<0.001)compared with virus load 3- lg copies/mL. More than 48 months treatment with HAART had high rate of K103N/S mutation(OR=7.422,95%CI=1.637-33.651,P<0.001), compared with 6- months treatment. HAART with D4T was associated with high K65R mutation rate(P=0.044).Conclusion: The prevalence of HIV-1 drug resistance with complex patterns is higher among patients failed to HAART in Henan. Selecting more suitable antiretroviral treatment regimen is necessary to reduce the emergence of the drug resistant strains.

参考文献/References:

[1] STEEGEN K,LUCHTERS S,DAUWE K,et al.Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya[J].AIDS Res Ther,2009,6(12):12
[2] SHAFER RW,RHEE SY,PILLAY D,et al.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance[J].AIDS,2007,21(2):215
[3] MARCONI VC,SUNPATH H,LU Z,et al.Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa[J].Clin Infect Dis,2008,46(10):1589
[4] 王征桦,吴守丽,张春阳,等.2008-2013年福建省HIV-1毒株耐药基因变异研究[J].中国人兽共患病学报,2015,31(4):330
[5] LAURENT C,TCHATCHUENG MBOUGUA JB,NGOM GUÉYE NF,et al.Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal[J].Trop Med Int Health,2011,16(2):217
[6] 李韩平,李宏,杨坤,等.河南省部分艾滋病患者抗病毒治疗的临床效果以及基因型耐药分析[J].中华微生物学和免疫学杂志,2005,25(3):194
[7] WAINBERG MA,ZAHARATOS GJ,BRENNER BG.Development of antiretroviral drug resistance[J].N Engl J Med,2011,365(7):637
[8] ZHANG Z,XU W,KOH YH,et al.A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors[J].Antimicrob Agents Chemother,2007,51(2):429
[9] HOSSEINIPOUR MC,GUPTA RK,VAN ZYL G,et al.Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings[J].J Infect Dis,2013,207(Suppl 2):S49
[10]BARTH RE,VAN DER LOEFF MF,SCHUURMAN R,et al.Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review[J].Lancet Infect Dis,2010,10(3):155
[11]DIALLO K,GÖTTE M,WAINBERG MA.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase[J].Antimicrob Agents Chemother,2003,47(11):3377
[12]KULKARNI R,BABAOGLU K,LANSDON EB,et al.The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness[J].J Acquir Immune Defic Syndr,2012,59(1):47
[13]TANG MW,RHEE SY,BERTAGNOLIO S,et al.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine[J].J Infect Dis,2013,207(Suppl 2):S70

相似文献/References:

[1]李晓菲),余祖江),梁红霞),等.艾滋病患者抗病毒督导治疗疗效分析*[J].郑州大学学报(医学版),2013,(02):235.
 LI Xiaofei),YU Zujiang),LIANG Hongxia),et al.Analysis on effects of HAART from 377 Chinese AIDS[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(05):235.
[2]李媛媛,张程达,郗园林,等.HIV/HCV合并感染者的生物学特征与生存分析*[J].郑州大学学报(医学版),2015,(03):371.
 LI Yuanyuan,ZHANG Chengda,XI Yuanlin,et al.Biological characteristics and survival analysis in HIV/HCV coinfected patients[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(05):371.
[3]曹新广),吕慧芳),陈贝贝),等.Axl调控的miRNA表达在NSCLC吉非替尼获得性耐药中的意义[J].郑州大学学报(医学版),2015,(05):651.
 CAO Xinguang),LV Huifang),CHEN Beibei),et al.Axl-modulated miRNA regulates gefitinib-resistance in lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(05):651.

备注/Memo

备注/Memo:
*河南省重点科技攻关计划项目 102102310003,112102310005; 河南省卫生科技创新型人才工程专项经费资助项目 2010年
#通信作者,男,1972年2月生,博士,副主任医师,研究方向:艾滋病防治,E-mail:Hongweiliu36@163.com
更新日期/Last Update: 2016-08-20